Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment

Marco Ragusa, Alessandra Majorana, Luisa Statello, Marco Maugeri, Loredana Salito, Davide Barbagallo, Maria Rosa Guglielmino, Laura R. Duro, Rosario Angelica, Rosario Caltabiano, Antonio Biondi, Maria Di Vita, Giuseppe Privitera, Marina Scalia, Alessandro Cappellani, Enrico Vasquez, Salvatore Lanzafame, Francesco Basile, Cinzia Di Pietro, Michele Purrello

Research output: Contribution to journalArticle

Abstract

The relationship between therapeutic response and modifications of microRNA (miRNA) transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by profiling the expression of 667 miRNAs in 2 human CRC cell lines, one sensitive and the other resistant to cetuximab (Caco-2 and HCT-116, respectively), through TaqMan real-time PCR. Caco-2 and HCT-116 expressed different sets of miRNAs after treatment. Specifically, 21 and 22 miRNAs were differentially expressed in Caco-2 or HCT-116, respectively (t test, P ≤ 0.01). By testing the expression of differentially expressed miRNAs in CRC patients, we found that miR-146b-3p and miR-486-5p are more abundant in K-ras-mutated samples with respect to wild-type ones (Wilcoxon test, P ≤ 0.05). Sixty-seven percent of differentially expressed miRNAs were involved in cancer, including CRC, whereas 19 miRNA targets had been previously reported to be involved in the cetuximab pathway and CRC. We identified 25 transcription factors putatively controlling these miRNAs, 11 of which have been already reported to be involved in CRC. On the basis of these data, we suggest that the downregulation of let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. Global network functional analysis (based on miRNA targets) showed a significant overrepresentation of cancer-related biological processes and networks centered on critical nodes involved in epidermal growth factor receptor internalization and ubiquitin-mediated degradation. The identification of miRNAs, whose expression is linked to the efficacy of therapy, should allow the ability to predict the response of patients to treatment and possibly lead to a better understanding of the molecular mechanisms of drug response.

Original languageEnglish
Pages (from-to)3396-3409
Number of pages14
JournalMolecular Cancer Therapeutics
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

MicroRNAs
Transcriptome
Colorectal Neoplasms
Therapeutics
Cetuximab
Biological Phenomena
Ubiquitin
Epidermal Growth Factor Receptor
Real-Time Polymerase Chain Reaction
Neoplasms
Transcription Factors
Up-Regulation
Down-Regulation
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. / Ragusa, Marco; Majorana, Alessandra; Statello, Luisa; Maugeri, Marco; Salito, Loredana; Barbagallo, Davide; Guglielmino, Maria Rosa; Duro, Laura R.; Angelica, Rosario; Caltabiano, Rosario; Biondi, Antonio; Di Vita, Maria; Privitera, Giuseppe; Scalia, Marina; Cappellani, Alessandro; Vasquez, Enrico; Lanzafame, Salvatore; Basile, Francesco; Di Pietro, Cinzia; Purrello, Michele.

In: Molecular Cancer Therapeutics, Vol. 9, No. 12, 12.2010, p. 3396-3409.

Research output: Contribution to journalArticle

Ragusa, M, Majorana, A, Statello, L, Maugeri, M, Salito, L, Barbagallo, D, Guglielmino, MR, Duro, LR, Angelica, R, Caltabiano, R, Biondi, A, Di Vita, M, Privitera, G, Scalia, M, Cappellani, A, Vasquez, E, Lanzafame, S, Basile, F, Di Pietro, C & Purrello, M 2010, 'Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment', Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3396-3409. https://doi.org/10.1158/1535-7163.MCT-10-0137
Ragusa, Marco ; Majorana, Alessandra ; Statello, Luisa ; Maugeri, Marco ; Salito, Loredana ; Barbagallo, Davide ; Guglielmino, Maria Rosa ; Duro, Laura R. ; Angelica, Rosario ; Caltabiano, Rosario ; Biondi, Antonio ; Di Vita, Maria ; Privitera, Giuseppe ; Scalia, Marina ; Cappellani, Alessandro ; Vasquez, Enrico ; Lanzafame, Salvatore ; Basile, Francesco ; Di Pietro, Cinzia ; Purrello, Michele. / Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 12. pp. 3396-3409.
@article{8cdef3bc9033464f90492da0da6e8950,
title = "Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment",
abstract = "The relationship between therapeutic response and modifications of microRNA (miRNA) transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by profiling the expression of 667 miRNAs in 2 human CRC cell lines, one sensitive and the other resistant to cetuximab (Caco-2 and HCT-116, respectively), through TaqMan real-time PCR. Caco-2 and HCT-116 expressed different sets of miRNAs after treatment. Specifically, 21 and 22 miRNAs were differentially expressed in Caco-2 or HCT-116, respectively (t test, P ≤ 0.01). By testing the expression of differentially expressed miRNAs in CRC patients, we found that miR-146b-3p and miR-486-5p are more abundant in K-ras-mutated samples with respect to wild-type ones (Wilcoxon test, P ≤ 0.05). Sixty-seven percent of differentially expressed miRNAs were involved in cancer, including CRC, whereas 19 miRNA targets had been previously reported to be involved in the cetuximab pathway and CRC. We identified 25 transcription factors putatively controlling these miRNAs, 11 of which have been already reported to be involved in CRC. On the basis of these data, we suggest that the downregulation of let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. Global network functional analysis (based on miRNA targets) showed a significant overrepresentation of cancer-related biological processes and networks centered on critical nodes involved in epidermal growth factor receptor internalization and ubiquitin-mediated degradation. The identification of miRNAs, whose expression is linked to the efficacy of therapy, should allow the ability to predict the response of patients to treatment and possibly lead to a better understanding of the molecular mechanisms of drug response.",
author = "Marco Ragusa and Alessandra Majorana and Luisa Statello and Marco Maugeri and Loredana Salito and Davide Barbagallo and Guglielmino, {Maria Rosa} and Duro, {Laura R.} and Rosario Angelica and Rosario Caltabiano and Antonio Biondi and {Di Vita}, Maria and Giuseppe Privitera and Marina Scalia and Alessandro Cappellani and Enrico Vasquez and Salvatore Lanzafame and Francesco Basile and {Di Pietro}, Cinzia and Michele Purrello",
year = "2010",
month = "12",
doi = "10.1158/1535-7163.MCT-10-0137",
language = "English",
volume = "9",
pages = "3396--3409",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment

AU - Ragusa, Marco

AU - Majorana, Alessandra

AU - Statello, Luisa

AU - Maugeri, Marco

AU - Salito, Loredana

AU - Barbagallo, Davide

AU - Guglielmino, Maria Rosa

AU - Duro, Laura R.

AU - Angelica, Rosario

AU - Caltabiano, Rosario

AU - Biondi, Antonio

AU - Di Vita, Maria

AU - Privitera, Giuseppe

AU - Scalia, Marina

AU - Cappellani, Alessandro

AU - Vasquez, Enrico

AU - Lanzafame, Salvatore

AU - Basile, Francesco

AU - Di Pietro, Cinzia

AU - Purrello, Michele

PY - 2010/12

Y1 - 2010/12

N2 - The relationship between therapeutic response and modifications of microRNA (miRNA) transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by profiling the expression of 667 miRNAs in 2 human CRC cell lines, one sensitive and the other resistant to cetuximab (Caco-2 and HCT-116, respectively), through TaqMan real-time PCR. Caco-2 and HCT-116 expressed different sets of miRNAs after treatment. Specifically, 21 and 22 miRNAs were differentially expressed in Caco-2 or HCT-116, respectively (t test, P ≤ 0.01). By testing the expression of differentially expressed miRNAs in CRC patients, we found that miR-146b-3p and miR-486-5p are more abundant in K-ras-mutated samples with respect to wild-type ones (Wilcoxon test, P ≤ 0.05). Sixty-seven percent of differentially expressed miRNAs were involved in cancer, including CRC, whereas 19 miRNA targets had been previously reported to be involved in the cetuximab pathway and CRC. We identified 25 transcription factors putatively controlling these miRNAs, 11 of which have been already reported to be involved in CRC. On the basis of these data, we suggest that the downregulation of let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. Global network functional analysis (based on miRNA targets) showed a significant overrepresentation of cancer-related biological processes and networks centered on critical nodes involved in epidermal growth factor receptor internalization and ubiquitin-mediated degradation. The identification of miRNAs, whose expression is linked to the efficacy of therapy, should allow the ability to predict the response of patients to treatment and possibly lead to a better understanding of the molecular mechanisms of drug response.

AB - The relationship between therapeutic response and modifications of microRNA (miRNA) transcriptome in colorectal cancer (CRC) remains unknown. We investigated this issue by profiling the expression of 667 miRNAs in 2 human CRC cell lines, one sensitive and the other resistant to cetuximab (Caco-2 and HCT-116, respectively), through TaqMan real-time PCR. Caco-2 and HCT-116 expressed different sets of miRNAs after treatment. Specifically, 21 and 22 miRNAs were differentially expressed in Caco-2 or HCT-116, respectively (t test, P ≤ 0.01). By testing the expression of differentially expressed miRNAs in CRC patients, we found that miR-146b-3p and miR-486-5p are more abundant in K-ras-mutated samples with respect to wild-type ones (Wilcoxon test, P ≤ 0.05). Sixty-seven percent of differentially expressed miRNAs were involved in cancer, including CRC, whereas 19 miRNA targets had been previously reported to be involved in the cetuximab pathway and CRC. We identified 25 transcription factors putatively controlling these miRNAs, 11 of which have been already reported to be involved in CRC. On the basis of these data, we suggest that the downregulation of let-7b and let-7e (targeting K-ras) and the upregulation of miR-17* (a CRC marker) could be considered as candidate molecular markers of cetuximab resistance. Global network functional analysis (based on miRNA targets) showed a significant overrepresentation of cancer-related biological processes and networks centered on critical nodes involved in epidermal growth factor receptor internalization and ubiquitin-mediated degradation. The identification of miRNAs, whose expression is linked to the efficacy of therapy, should allow the ability to predict the response of patients to treatment and possibly lead to a better understanding of the molecular mechanisms of drug response.

UR - http://www.scopus.com/inward/record.url?scp=78650505164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650505164&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0137

DO - 10.1158/1535-7163.MCT-10-0137

M3 - Article

C2 - 20881268

AN - SCOPUS:78650505164

VL - 9

SP - 3396

EP - 3409

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -